Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

CER: Who Can Say What, and When Can They Say It?

E.V.I.dently, November 2011 By Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council

With billions of dollars in comparative effectiveness research (CER) set for completion in coming years, there will be broader discussions about the findings and what those findings might mean for patients and other health care decision makers. A parallel discussion will be conducted around questions regarding who can discuss and share these CER findings publicly? Who has access to the data that was used to generate the CER? These are just some of the pressing questions that are being raised by health care stakeholders as CER becomes more prevalent. Let's take a closer look at these issues:

Access to Data

Today there are a number of databases that are mined for comparative effectiveness research and other health care studies. Some are proprietary databases operated by payers, academic research institutions, or the pharmaceutical industry, while others are taxpayer-funded and government operated (FDA AERS, NHANES). In anticipation of the wide range of CER, however, a number of new databases are being developed by both private and public sector organizations. 

What’s unclear is the nature of the access that will be granted to these new databases, particularly if different groups want to affirm or disprove the CER that was developed from that data or review the research methodology. In general, having access to this information could be important for optimal patient care management. With some oversight, broader access to public databases such as Sentinel and Janus, as well as databases funded by the Patient-Centered Outcomes Research Institute, could be a good start.

Communicating Information

The pharmaceutical industry is highly regulated when it comes to discussing health care information, while other groups have wide latitude—or even complete freedom—in what they can say. While there are valid reasons for the regulation of some communication (marketing messages and materials, for example), there also are instances where it would be in the greater interest of public health for the sponsor of a particular drug to be allowed to respond to research or easily correct misinformation beyond solicited medical information. When it comes to CER, would the industry be able to discuss or share those studies, or even call for corrections on ones with serious flaws?

Communicating to Physicians

CER will be further amplified through academic detailing initiatives, in which government or academic institutions train health experts to discuss CER with physicians. In the United States, the Agency for Healthcare Research and Quality is leading the multi-million dollar federal initiative that will start off by targeting 1,500 primary care physicians and health systems. The federal government is not alone in its efforts – states including Vermont, Pennsylvania, South Carolina and Maine have been conducting academic detailing for a number of years.

Additionally, CER information will be further disseminated via continuing medical education programs and payer review guides, which are currently in development.  

These programs can be useful in providing physicians and payers with information that they might not have been aware of otherwise. However, it is not clear as to where the checks and balances may exist in the oversight of government-sponsored detailing, in the same way it is required of industry. 

Challenges for Patients

There are thousands of pages of health information available on the Internet, in medical journals, and other sources. Sifting through the information is daunting for a health care professional, let alone a patient. With more information becoming available, it will be even more important to ensure that patients have access to a broad amount of correct, verified information and know where to find it.

Unfortunately, sometimes incorrect information is shared broadly—U.S. Rep. Michelle Bachmann’s recent public statements about a vaccine is just one example—and it can be difficult to quickly correct the misinformation and make sure that consumers are properly educated. Acting on poor or faulty information could lead to serious health consequences for patients.

What will it take to address these challenges? It’s too early to know for sure, but a decision on U.S. vs. Caronia, a case pending in the U.S. Court of Appeals for the Second Circuit, could have implications for the pharmaceutical industry. At issue in Caronia is whether the First Amendment protects the right of individuals to speak truthfully about off-label uses of FDA-approved products. The question is whether a decision in the case will have broader applicability to CER and other health-related studies.

Next Steps

The challenges related to conducting, disseminating and communicating CER won’t be solved overnight. But it is important to begin considering how these questions might be addressed, and to their credit, organizations like the Agency for Healthcare Research and Quality, are beginning to discuss these issues. To further the dialogue, NPC will be hosting a conference in early 2012 to explore the asymmetry of communications and data access issues in greater detail. It’s important to consider all of the aspects of this issue, because having the right information is critical for patients and health care providers.

For additional information on asymmetry, view our interviews with patients, health care and legal experts. 

Newsletter Volume

E.V.I.dently April 2015

MessageThe Health Care Paradigm Shift: Moving From Volume to ValueAs our health care payment and delivery systems shift from volume-based to...
Blog Post

CER Tweets of the Week: NPC in The RPM Report, New PCORI CDR Advisory Panel Members (April 20-24)

This week, comparative effectiveness research (CER) stakeholders on Twitter shared a commentary on CER and the environment for health care decision-...
Blog Post

CER Tweets of the Week: NPC Survey on Medicaid Directors’ CER Views; EU/USA CER Expectations; #HIMSS15 (April 13-17)

This week, comparative effectiveness research (CER) stakeholders welcomed data from the National Pharmaceutical Council’s (@npcnow) survey assessing...
Blog Post

CER Tweets of the Week: NPC and PCORI at AMCP 27th Annual Meeting & Expo (April 6-10)

This week, comparative effectiveness research (CER) stakeholders tweeted from the Academy of Managed Care Pharmacy’s 27th Annual Meeting and Expo (#...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Press Release

National Pharmaceutical Council, Discern Health Examine Accountable Care Measures for Specialty Care and Innovative Treatment

Washington, DC (October 28, 2014)— Measuring the quality and cost of health care is an integral part of accountable care, but new research from the...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Mind the Gap: Improving Quality Measurement in Accountable Care Systems

The National Pharmaceutical Council's (NPC) webinar, Mind the Gap: Improving Quality Measurement in Accountable Care Systems, was moderated by...
YouTube Videos

Why are quality measures important? We asked health care thought leaders to tell us why.

Quality measurement, tied to financial incentives, is one of many approaches accountable care programs are using to promote system-wide improvement....
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
Blog Post

CER Tweets of the Week: NPC in The RPM Report, New PCORI CDR Advisory Panel Members (April 20-24)

This week, comparative effectiveness research (CER) stakeholders on Twitter shared a commentary on CER and the environment for health care decision-...
Blog Post

CER Tweets of the Week: NPC Survey on Medicaid Directors’ CER Views; EU/USA CER Expectations; #HIMSS15 (April 13-17)

This week, comparative effectiveness research (CER) stakeholders welcomed data from the National Pharmaceutical Council’s (@npcnow) survey assessing...
Blog Post

CER Tweets of the Week: NPC and PCORI at AMCP 27th Annual Meeting & Expo (April 6-10)

This week, comparative effectiveness research (CER) stakeholders tweeted from the Academy of Managed Care Pharmacy’s 27th Annual Meeting and Expo (#...
Blog Post

#TBT: National Minority Health Month & Health Equity

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
cersurvey-15

2015 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's fifth annual survey, "Comparative Effectiveness Research (CER) and the Environment for Health...

Accountable Care Measures for High-Cost Specialty Care and Innovative Treatment

This research sheds light on gaps in quality measurement and missed opportunities to promote...
  •  
  • 1 of 22
  • >